The Safety of Thoracentesis, Tunneled Pleural Catheter, and Chest Tubes in Patients Taking Novel Oral Anti-Coagulants

Yale University

Status: Completed

Conditions: Pleural Effusion; Thoracic Effusion

Treatments: Drug: Novel Oral Anti-Coagulants

Study type: Observational

Funder types: Other

Identifiers

NCT03535883

No NIH funding (Other Identifier)

2000021542

Details and patient eligibility

About

To assess risks of bleeding in those individuals receiving Novel Oral Anti-Coagulant (NOAC) medications, admitted to the hospital and require thoracentesis, chest tube or tunneled pleural catheter placement.

Full description

The research component of this study simply observes and documents the outcomes of these procedures. Patients will undergo an analysis of their pre-procedural hematocrit and this will be compared to their post-procedural (next day) hematocrit.

Enrollment: 590 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Age > 18 y/o
2. Unilateral or bilateral pleural effusion
3. Ability to provide consent or consent given for the procedure and research study

Exclusion criteria

Adults who refuse to provide consent.

Trial design

590 participants in 2 patient groups

patients taking NOAC's

Description:

Patients with unilateral or bilateral pleural effusions who undergo thoracentesis, chest tube, or pleurx placement and are taking Novel Oral Anti-Coagulants (NOAC).

Treatment:

Drug: Novel Oral Anti-Coagulants

patients not taking NOAC's

Description:

Patients with unilateral or bilateral pleural effusions who undergo thoracentesis, chest tube, or pleurx placement who are not taking Novel Oral Anti-Coagulants (NOAC).